Takeda

Takeda’s ADZYNMA Approved by FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura Takeda has received FDA approval for ADZYNMA (ADAMTS13, recombinant-krhn) for both prophylactic and on-demand treatment in adults and pediatri...

HUTCHMED Completes Rolling Submission of NDA to FDA for Fruquintinib HUTCHMED (China) Limited announced the completion of the rolling submission of a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") for fruquintinib, its highly selective and potent oral inhibitor of VEGFR-1,...

Actinium Announces Positive Full Data Results From the Pivotal Phase III SIERRA Trial Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, announced positive primary and secondary endpoint results from its pivotal Phase III SIERRA trial of Iomab-B in patients aged 55 and older...

Ipsen to Acquire Albireo for USD 952 Million Ipsen, a French pharmaceutical company, has offered USD 42 per share for the US biotech Albireo and its rare disease treatment Bylvay, continuing a recent spree of merger and acquisition activity. Albireo, a Boston-based business, is valued at USD 952 million under th...

Valo Health receives USD 110 Million Series B from Koch Valo Health launched in September with USD 100 million and a couple of acquisitions under its belt to transform drug development and cut years off R&D timelines. Now, it is filling with USD 110 million from Koch Disruptive Technologies that will bolster...

Merck's Keytruda-Eisai's Lenvima Combo Make the Cut in Renal Cancer Numerous immunotherapy-based combinations are already trying in the old game of gleek to stake up some share in previously untreated, metastatic kidney cancer; however, the market seems to expand as the new entrants continue to make their entry....

BASE10 Collaborates with DNA Link for COVID-19 Antibody Test Research US-based BASE10 Genetics and Korean firm DNA Link announced a collaboration on a research project to appraise the usability of the DNA Link's antibody test, AccuFind COVID-19 IgG, in a healthcare setting. Currently, most antibody tests avai...

The Gastroparesis market size in the 7MM was found to be USD 3,170.01 million in 2019 and is anticipated to increase at a CAGR for the study period 2017-2030 owing to dynamic pipeline therapies in the mid-/ late-stage clinical development and rising gastroparesis prevalence. Gastroparesis or Delayed gastric emp...

The contribution of key pharma companies, such as 9 Meters Biopharma, ImmunogenX, Provention Bio, Cour Pharmaceuticals/Takeda, Precigen ActoBio, Falk Pharma, and Zedira is significant in driving Celiac disease market size. Who would have thought that consumption of gluten can trigger an autoimmune disorder? Alth...

ImaginAb has collaborated with AstraZeneca, Pfizer and Takeda to develop technology to facilitate tumour imaging and monitoring inside the cells. ImaginAb is an emerging imaging company focused on immune-oncology. The technology also helps in targeting and visualizing CD8+ T cells, which are activated by the im...